Introduction {#S0001}
============

*RET* fusion genes such as *KIF5B-RET* and *CCDC6-RET* have recently been identified in non--small cell lung cancer (NSCLC).[@CIT0001],[@CIT0002] Several clinical trials are already under way to evaluate the therapeutic effects of tyrosine kinase inhibitors whose targets include RET---such as vandetanib, cabozantinib, and alectinib---in individuals with *RET* fusion--positive NSCLC, with some patients having shown marked treatment responses.[@CIT0003],[@CIT0004] However, no selective RET inhibitor has yet been approved specifically for RET-driven lung cancer, and it has remained unclear whether such patients manifest a sensitivity to cytotoxic chemotherapy similar to that of other NSCLC patients. We here report a case of *RET* fusion--positive NSCLC that showed long-term benefit from treatment with pemetrexed.

Case report {#S0002}
===========

A 63-year-old female never-smoker with stage IV lung adenocarcinoma was enrolled in an ongoing observational study to evaluate the feasibility of the application of next-generation sequencing to mutation analysis of lung cancer specimens at Kindai University.[@CIT0005] The multiplex genetic testing identified a *CCDC6-RET* fusion gene in tissue specimens obtained from the patient for lung cancer diagnosis ([Figure 1A](#F0001){ref-type="fig"}). We verified this chromosomal inversion by fluorescence in situ hybridization with probes that flank the *RET* translocation site identified in tumors positive for the *CCDC6-RET* fusion ([Figure 1B](#F0001){ref-type="fig"}). The patient was treated with several lines of therapy, including platinum-based chemotherapy, docetaxel plus an experimental multikinase inhibitor, erlotinib plus an investigational drug, and an investigational antiangiogenic agent. Pemetrexed at a dose of 500 mg/m^2^ every 3 weeks was then initiated as a fifth-line therapy. After 7 weeks of pemetrexed administration, computed tomography revealed shrinkage of the primary lung lesion ([Figure 1C](#F0001){ref-type="fig"}), which was ultimately categorized as a partial response. The serum carcinoembryonic antigen (CEA) level had decreased markedly by this time and remained low thereafter throughout the period of tumor regression ([Figure 2](#F0002){ref-type="fig"}). Anemia of grade 3 and an aspartate aminotransferase elevation of grade 3 occurred during the first treatment cycle, but no severe adverse events were subsequently noted after the pemetrexed dose was reduced to 400 mg/m^2^. A total of 40 treatment cycles for pemetrexed was administered over 30 months until disease progression.Figure 1(**A**) Junction reads for *CCDC6-RET* fusion transcripts as determined by next-generation sequencing of tumor cDNA from the patient. (**B**) Fluorescence in situ hybridization analysis of tumor tissue from the patient with break-apart probes for *RET* (5′ probe, green; 3′ probe, red). The *RET* rearrangement is indicated by the presence of a single isolated red signal (arrowhead). (**C**) Chest computed tomography scans of the patient before, 7 weeks after, and 23 months after initiation of treatment with pemetrexed and carboplatin.Figure 2Time course of serum CEA level for the patient after initiation of pemetrexed treatment at time zero.**Abbreviations:** CEA, carcinoembryonic antigen; PD, progressive disease.

Discussion {#S0003}
==========

*RET* fusion genes have recently been identified in a subset of NSCLC tumors, being detected most often in patients who are never-smokers, are of a younger age, and have tumors with an adenocarcinoma histology. Multikinase inhibitors with activity against RET have shown marked clinical efficacy in NSCLC patients harboring *RET* fusions,[@CIT0003],[@CIT0004] but it has remained unclear whether such patients might receive benefit from cytotoxic chemotherapy. The present case shows long-term efficacy of pemetrexed for \>2 years in the fifth-line setting. Preliminary data from a phase III study (PROFILE 1007) comparing crizotinib with pemetrexed or docetaxel chemotherapy after failure of one prior platinum-based chemotherapy regimen have shown that pemetrexed treatment produced a better outcome compared with docetaxel in patients with *ALK* fusion--positive NSCLC.[@CIT0006] Moreover, two retrospective studies have suggested that *EML4-ALK*--positive patients may have a superior progression-free survival when treated with pemetrexed-based therapies compared with patients with other molecularly defined subtypes of NSCLC.[@CIT0007],[@CIT0008] Given the importance of a low level of thymidylate synthase (TS) expression for sensitivity to pemetrexed-based regimens,[@CIT0009] a low TS expression level of the proband may have contributed to the long-term efficacy of pemetrexed.[@CIT0010] Similar to lung tumors positive for *ALK* rearrangement, a recent study also showed that *RET* fusion--positive lung cancers were sensitive to pemetrexed-based therapies, although data for TS expression were not available.[@CIT0011] TS-targeting agents such as pemetrexed and S-1 may thus offer promising treatment options for patients with *RET* fusion--positive NSCLC.

In conclusion, we report the successful long-term treatment of a *RET* fusion--positive NSCLC patient with pemetrexed. Given the insufficient data regarding pemetrexed sensitivity and *RET* fusion, further investigations are warranted to investigate these biological mechanisms.

Patient consent {#S0004}
===============

Written informed consent was obtained from the patient for publication of this case report and accompanying images before the patient received chemotherapy. Institutional approval was not necessary to publish a case report.
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